Class
Article
College
College of Agriculture and Applied Sciences
Department
Animal, Dairy, and Veterinary Sciences Department
Faculty Mentor
Brett Hurst
Presentation Type
Poster Presentation
Abstract
Introduction
Animal models are key to the research and development of antiviral interventions. Two strains of low-pathogenic avian influenza virus, A/Anhui/1/2013 and A/Shanghai/1/2013 (H7N9), isolated from a 2013 outbreak in China and acquired by USU’s Institute for Antiviral Research from the CDC, are the subject of this project.
Developing antiviral interventions against Influenza A H7N9 is essential because:
• Global outbreaks have caused high mortality among bird and human populations since 2013.[1]
• Low-pathogenic avian flu viruses can mutate to become highly pathogenic.[2]
• No current prophylactic or therapeutic human interventions exist.[3]
BALB/c mice, commonly used for antiviral research, are not naturally susceptible to H7N9 infection, as they lack the appropriate sialic acid receptors in their respiratory tissue. To create animal models for future in-vivo antiviral studies, this project aims to: adapt these virus strains to infect BALB/c mice and determine a 90% Lethal Dose (LD90).
Location
Logan, UT
Start Date
4-9-2025 3:30 PM
End Date
4-9-2025 4:20 PM
Included in
Adaptation of Influenza A Virus Strains A/Anhui/1/2013 (H7N9) and A/Shanghai/1/2013 (H7N9) For Development of Effective Mouse Models
Logan, UT
Introduction
Animal models are key to the research and development of antiviral interventions. Two strains of low-pathogenic avian influenza virus, A/Anhui/1/2013 and A/Shanghai/1/2013 (H7N9), isolated from a 2013 outbreak in China and acquired by USU’s Institute for Antiviral Research from the CDC, are the subject of this project.
Developing antiviral interventions against Influenza A H7N9 is essential because:
• Global outbreaks have caused high mortality among bird and human populations since 2013.[1]
• Low-pathogenic avian flu viruses can mutate to become highly pathogenic.[2]
• No current prophylactic or therapeutic human interventions exist.[3]
BALB/c mice, commonly used for antiviral research, are not naturally susceptible to H7N9 infection, as they lack the appropriate sialic acid receptors in their respiratory tissue. To create animal models for future in-vivo antiviral studies, this project aims to: adapt these virus strains to infect BALB/c mice and determine a 90% Lethal Dose (LD90).